var title_f35_21_36176="Cutaneous polyarteritis nodosa";
var content_f35_21_36176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous polyarteritis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerated, erythematous nodules in polyarteritis nodosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36176=[""].join("\n");
var outline_f35_21_36176=null;
var title_f35_21_36177="Hand splint";
var content_f35_21_36177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Splint immobilization of an infected hand protects the affected area, limits opening of tissue planes restricting the spread of infection, and decreases pain. Splinting in a position of function can help protect against flexion contractures, reduce stiffness, and hasten rehabilitation. This illustrates a volar splint used to maintain the hand in a functional position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36177=[""].join("\n");
var outline_f35_21_36177=null;
var title_f35_21_36178="Homeostenosis";
var content_f35_21_36178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Homeostenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from: Taffet GE. Physiology of aging. In: Cassel CK, Leipzig RM, Cohen HJ, et al [eds]. Geriatric Medicine: An Evidence-Based Approach, 4th ed. New York, Springer, 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36178=[""].join("\n");
var outline_f35_21_36178=null;
var title_f35_21_36179="Patient information: Giving your child over-the-counter medicines (The Basics)";
var content_f35_21_36179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16587\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/39/19066\">",
"         The different parts of a medicine label (Drug Facts)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/2/43041\">",
"         Patient information: Constipation in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/49/43793\">",
"         Patient information: Diaper rash (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/30/6626\">",
"         Patient information: Eczema (atopic dermatitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/10/13475\">",
"         Patient information: Seasonal allergies in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/8/41092\">",
"         Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/23/15730\">",
"         Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/7/15477\">",
"         Patient information: Constipation in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/41/44690\">",
"         Patient information: Diaper rash in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/44/40643\">",
"         Patient information: The common cold in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Giving your child over-the-counter medicines (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/giving-your-child-over-the-counter-medicines-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12539642\">",
"      <span class=\"h1\">",
"       What are over-the-counter medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Over-the-counter (OTC) medicines are medicines that you can buy in a pharmacy or store without a doctor&rsquo;s prescription. They come in different forms, including pills, creams, and eye drops.",
"     </p>",
"     <p>",
"      OTC medicines are commonly used to treat:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Cough and cold",
"       </li>",
"       <li>",
"        Allergies",
"       </li>",
"       <li>",
"        Skin rashes, diaper rashes, or hives",
"       </li>",
"       <li>",
"        Diarrhea or constipation (trouble having bowel movements)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some OTC medicines can cure conditions (such as rashes), but many only treat symptoms for a short time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539657\">",
"      <span class=\"h1\">",
"       How do I know the correct dose of medicine for my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To figure out the correct dose, you need to look at the medicine&rsquo;s &ldquo;Drug Facts&rdquo; label (",
"      <a class=\"graphic graphic_figure graphicRef73468 \" href=\"mobipreview.htm?18/39/19066\">",
"       figure 1",
"      </a>",
"      ). The section called &ldquo;Directions&rdquo; tells you how much medicine to use and how often to use it.",
"     </p>",
"     <p>",
"      The dose might depend on your child&rsquo;s weight. If you do not know your child&rsquo;s weight, use the dosage for his or her age.",
"     </p>",
"     <p>",
"      To give your child the correct dose, make sure to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use the dosing device that comes with the medicine. If the medicine doesn&rsquo;t have a dosing device, ask the pharmacy, doctor, or nurse for one.",
"       </li>",
"       <li>",
"        Read the directions every time, even if you have given the medicine to your child before. Medicines can come in different strengths. Also, companies sometimes change medicines and doses.",
"       </li>",
"       <li>",
"        Follow the directions carefully. Do not give your child more medicine than directed. Giving your child extra medicine will not make him or her feel better, and it can cause serious problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539672\">",
"      <span class=\"h1\">",
"       Can OTC medicines cause side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. OTC medicines can cause side effects. The side effects depend on the medicine. Children are more likely to get side effects from OTC medicines than adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539687\">",
"      <span class=\"h1\">",
"       Can I give my child 2 or more OTC medicines at the same time?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the medicines and their &ldquo;active ingredient.&rdquo; The active ingredient is the part of the medicine that treats symptoms. Every medicine has at least 1 active ingredient.",
"     </p>",
"     <p>",
"      To know what the active ingredient is, look at the Drug Facts label (",
"      <a class=\"graphic graphic_figure graphicRef73468 \" href=\"mobipreview.htm?18/39/19066\">",
"       figure 1",
"      </a>",
"      ). It&rsquo;s important to read the Drug Facts carefully, because medicines that treat different conditions can have the same active ingredient. For example, fever medicines and cough and cold medicines can have the same active ingredient.",
"     </p>",
"     <p>",
"      <strong>",
"       Do not give your child 2 medicines with the same active ingredient",
"      </strong>",
"      . Giving your child 2 medicines with the same active ingredient can cause an overdose. This can cause serious &ndash; and even life-threatening &ndash; problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539702\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call the doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your child has side effects or problems from an OTC medicine.",
"       </li>",
"       <li>",
"        Your child&rsquo;s symptoms don&rsquo;t get better or get worse after using an OTC medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539717\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talk to your child&rsquo;s doctor or nurse about OTC medicines at routine check-ups, before your child gets sick. Ask him or her which medicines you should use, when to use them, and how to use them. That way, if your child gets sick, you will know what to do.",
"       </li>",
"       <li>",
"        Ask questions if you are unsure which medicine to use or how to use it. You can ask the pharmacy worker or your child&rsquo;s doctor or nurse.",
"       </li>",
"       <li>",
"        Choose a medicine made to treat only the symptoms or condition your child has.",
"       </li>",
"       <li>",
"        Close the medicine tightly and store it out of your child&rsquo;s reach.",
"       </li>",
"       <li>",
"        Throw out medicine that has expired (gone bad).",
"       </li>",
"       <li>",
"        Teach your child that medicine shouldn&rsquo;t be eaten like candy, and that it can be dangerous to take too much.",
"       </li>",
"       <li>",
"        Keep the number for the Poison Control Center: 1-800-222-1222 (in the United States), in case your child gets too much medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should NOT:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give your child medicine made for adults, without first asking the doctor or nurse.",
"       </li>",
"       <li>",
"        Give cough and cold medicines to children younger than 6 years old. Cough and cold medicines can cause serious problems in young children. Plus, they are not likely to help with symptoms.",
"       </li>",
"       <li>",
"        Give",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        to children younger than 18 years old. It can cause a life-threatening condition called Reye syndrome in young people.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12539732\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=see_link\">",
"       Patient information: Eczema (atopic dermatitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/49/43793?source=see_link\">",
"       Patient information: Diaper rash (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=see_link\">",
"       Patient information: Constipation in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=see_link\">",
"       Patient information: Seasonal allergies in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"       Patient information: The common cold in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"       Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"       Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/41/44690?source=see_link\">",
"       Patient information: Diaper rash in infants and children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"       Patient information: Constipation in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/21/36179?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16587 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36179=[""].join("\n");
var outline_f35_21_36179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539642\">",
"      What are over-the-counter medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539657\">",
"      How do I know the correct dose of medicine for my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539672\">",
"      Can OTC medicines cause side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539687\">",
"      Can I give my child 2 or more OTC medicines at the same time?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539702\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539717\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12539732\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/39/19066\">",
"      The different parts of a medicine label (Drug Facts)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=related_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/41/44690?source=related_link\">",
"      Patient information: Diaper rash in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=related_link\">",
"      Patient information: Seasonal allergies in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_21_36180="Quazepam: Patient drug information";
var content_f35_21_36180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/39/30326?source=see_link\">",
"     see \"Quazepam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702834",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703741",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or sleep apnea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet may be broken in half.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11009 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36180=[""].join("\n");
var outline_f35_21_36180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024172\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024174\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024173\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024178\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024179\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024181\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024176\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024177\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024182\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024183\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/39/30326?source=related_link\">",
"      Quazepam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_21_36181="Epirubicin: Patient drug information";
var content_f35_21_36181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epirubicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     see \"Epirubicin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ellence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ellence&reg;;",
"     </li>",
"     <li>",
"      Epirubicin for Injection;",
"     </li>",
"     <li>",
"      Epirubicin Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Pharmorubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease you may need a lower dose. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting some types of cancer. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to epirubicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3631224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A fast heartbeat, very bad heart disease, or have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had daunorubicin, doxorubicin, epirubicin, idarubicin, or mitoxantrone before, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Color of urine is orange or red for 1 to 2 days after getting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, no period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12422 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36181=[""].join("\n");
var outline_f35_21_36181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165602\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165603\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028753\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028755\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028754\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028759\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028760\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028762\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028757\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028758\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028763\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028764\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=related_link\">",
"      Epirubicin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_21_36182="CLL proliferation centers";
var content_f35_21_36182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node from a patient with CLL shows a diffuse infiltrative pattern. The best clues to the diagnosis are the pale-staining pseudofollicles (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36182=[""].join("\n");
var outline_f35_21_36182=null;
var title_f35_21_36183="Sternal aspiration sites";
var content_f35_21_36183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Sternal bone marrow puncture sites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Artist's drawing of the right anterior portion of the chest wall. The first three right intercostal spaces are marked in blue. The bone marrow aspirate needle should be inserted into the sternum either at the level of the 2nd or 3rd intercostal space. The needle is shown about to enter the sternum at the 3rd intercostal space, slightly to the right of center. However, most physicians prefer to enter the sternum in the midline (asterisks), placing fingers of the hand not holding the needle on either side of the sternum for guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36183=[""].join("\n");
var outline_f35_21_36183=null;
var title_f35_21_36184="Escitalopram: Pediatric drug information";
var content_f35_21_36184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Escitalopram: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"    see \"Escitalopram: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/1/44053?source=see_link\">",
"    see \"Escitalopram: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13502640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Canadian Product Labeling Updated in Regards to Risk of Cardiac Arrhythmias",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Heath Canada is notifying the Canadian public that escitalopram (Canadian brand name Cipralex&reg;) product monograph has been updated with warnings regarding dose-related risks for QT interval prolongation. The updated product monograph contraindicates use in patients with known QT interval prolongation or congenital long QT syndrome and recommends avoiding concomitant use of agents known to prolong the QT interval or reduce electrolyte concentrations. The maximum recommended dose of escitalopram is 20 mg/day for most patients, however a maximum of 10 mg/day is recommended for patients &gt;65 years of age, with hepatic dysfunction, or taking omeprazole or cimetidine.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Patients and their healthcare providers should discuss potential concerns (eg, existing heart disease, concomitant medications, low potassium or other electrolyte concentrations, or a strict diet) prior to initiating therapy. Patients are also advised to consult their healthcare provider when considering escitalopram dose reductions/discontinuation and to immediately report symptoms such as palpitations, fainting, dizziness, or seizures during therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at file://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_63-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F608961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cipralex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1011695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1011728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"      see \"Escitalopram: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 years: Limited data available; only one randomized, placebo-controlled trial has been published; efficacy was not demonstrated for children &lt;12 years of age (Wagner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;12 years: Initial: 10 mg once daily; may be increased to 20 mg/day after at least 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Autism and PDD:",
"     </b>",
"     Limited data available; based on one published prospective, 10-week, open-labeled, forced dose-titration trial of 28 children and adolescents 6-17 years of age (mean age: 10.4 years) (Owley, 2005). Mean severity outcome scores showed significant improvement; mean final dose: 11.1 &plusmn; 6.5 mg/day (range: 0-20 mg/day); no significant correlation between final tolerated dose and weight was shown; 10 of 28 treated subjects could not tolerate a 10 mg/day dose; further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 6-17 years: Initial: 2.5 mg once daily; may increase if needed to 5 mg/day after 1 week; may then increase at weekly intervals by 5 mg/day if needed and as tolerated; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder:",
"     </b>",
"     Limited data available; based on one prospective, 12-week, open-labeled trial of 20 children and adolescents 10-17 years of age (mean age: 15 years) (Isolan, 2007). At the end of the 12 weeks, 65% of patients met overall response criteria and all symptomatic and quality of life outcome measures showed significant improvements; mean final dose: 13 &plusmn; 4.1 mg/day; further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 10-17 years: Initial: 5 mg once daily for 7 days, then 10 mg/day for 7 days; may then increase at weekly intervals by 5 mg/day if needed, based on clinical response and tolerability; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Depression, generalized anxiety disorder:",
"     </b>",
"     Initial: 10 mg once daily; dose may be increased to 20 mg/day after at least 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adolescents &gt;12 years and Adults: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mg/mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 1 mg/mL (240 mL) [contains propylene glycol; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088620.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088620.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1011734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily (morning or evening); may be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1011718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1011696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder (FDA approved in ages 12-17 years and adults); treatment of generalized anxiety disorders (GAD) (FDA approved in adults); has also been studied in children and adolescents with social anxiety disorders and pervasive developmental disorders (PDD) including autism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lexapro&reg; may be confused with Loxitane&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zavesca: Brand name for escitalopram [in multiple international markets; ISMP April 21, 2010], but also brand name for miglustat [Canada, U.S., and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, dizziness, fatigue, headache, insomnia, lethargy, somnolence, yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Anorgasmia, libido decreased, menstrual disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, constipation, diarrhea, flatulence, indigestion, nausea, toothache, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculation disorder, impotence, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, neck/shoulder pain, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal cramps, acute renal failure, aggression, agitation, agranulocytosis, akathisia, allergic reaction, allergy, alopecia, amnesia, anaphylaxis, anemia, angioedema, anxiety, apathy, aplastic anemia, appetite increased, arthralgia, ataxia, atrial fibrillation, bilirubin increased, blurred vision, bradycardia, bronchitis, cardiac failure, cerebrovascular accident, chest pain, choreoathetosis, concentration impaired delirium, delusion, depersonalization, depression aggravated, dermatitis, diabetes mellitus, diplopia, DVT, dyskinesia, dysphagia, dyspnea, dystonia, dysuria, ecchymosis, edema, epistaxis, erythema multiforme, extrapyramidal symptoms, fever, flushing, gait abnormal, gastroenteritis, GERD, GI hemorrhage, glaucoma, hallucination, heartburn, hemolytic anemia, hepatic necrosis, hepatitis, hot flashes, hypercholesterolemia, hyper-/hypoglycemia, hypertensive crisis, hypertension, hypoesthesia, hypokalemia, hyponatremia, hypotension, INR increased, irritability, jaw stiffness, leukopenia, lightheadedness, limb pain, liver enzymes increased, liver failure, menorrhagia, menstrual cramps, migraine, muscle weakness, myalgia, mydriasis, myocardial infarction, myoclonus, nasal congestion, neuroleptic malignant syndrome, nightmares, nystagmus, orthostasis, palpitation, pancreatitis, panic reaction, paranoia, Parkinsonism, phlebitis, photosensitivity, priapism, prolactinemia, prothrombin decreased, psychosis, pulmonary embolism, QT prolonged, rash, rectal hemorrhage, rhabdomyolysis, seizures, serotonin syndrome, SIADH, sinus congestion, sinus headache, spontaneous abortion, Stevens-Johnson syndrome, suicidal tendency, suicide attempt, syncope, tachycardia, tardive dyskinesia, thrombocytopenia, thrombocytopenic purpura (idiopathic), thrombosis, tinnitus, torsade de pointes, toxic epidermal necrolysis, tremor, urinary frequency, urinary retention, urticaria, ventricular arrhythmia, ventricular tachycardia, vertigo, visual disturbance, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1011702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to escitalopram, citalopram, or any component; use with MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of pimozide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7689561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Escitalopram may impair platelet aggregation and cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); risk may be increased in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, warfarin, or other drugs that affect coagulation; bleeding related to SSRI or SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage. Escitalopram may impair cognitive or motor performance. SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006). Use with caution in patients with seizure disorders, concomitant illnesses that may affect hepatic metabolism or hemodynamic responses (eg, unstable cardiac disease, recent MI), and suicidal ideation; use with caution and decrease dose in patients with hepatic dysfunction; use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution during third trimester of pregnancy [newborns may experience adverse effects or withdrawal symptoms (consider risk:benefits); exposure to SSRIs late in pregnancy may also be associated with an increased risk for persistent pulmonary hypertension of the newborn (Chambers, 2006)]; high doses of escitalopram have been associated with teratogenicity in animals. Use with caution in patients receiving diuretics or those who are volume-depleted (may cause hyponatremia or SIADH). No clinical studies have assessed the combined use of escitalopram and electroconvulsive therapy; however, use with caution in patients receiving electroconvulsive therapy; may increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to electroconvulsive therapy treatment. Oral solution contains propylene glycol and sorbitol.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1011703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms may require discontinuation or modification of drug therapy. SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid abrupt discontinuation; withdrawal syndrome with discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, irritability, sensory disturbances, headache, lethargy, emotional lability, insomnia, tinnitus, and seizures) may occur if therapy is abruptly discontinued or dose is reduced; taper the dose to minimize risks of discontinuation symptoms. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Use with caution in patients with a history of mania. Escitalopram is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially fatal serotonin syndrome (SS) or neuroleptic malignant syndrome (NMS)-like reactions have occurred with selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs) when used alone and particularly when used in combination with serotonergic drugs (eg, triptans), drugs that impair the metabolism of serotonin (eg, MAO inhibitors, linezolid), or antidopaminergic agents (eg, antipsychotics). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs or symptoms arise and initiate supportive symptomatic therapy. Tryptophan (which can be metabolized to serotonin) and the herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     ) may increase serious side effects (concomitant use of these agents with escitalopram is not recommended).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Escitalopram. Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid the risk of escitalopram toxicity. Escitalopram Canadian product labeling recommends limiting escitalopram dose to 10 mg/day with concomitant use of cimetidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of Escitalopram. Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Escitalopram dosing recommendations may differ between international labelings in regards to concomitant use of omeprazole. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1011717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption is not affected by food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tryptophan supplements may increase serious side effects; its use is",
"     <b>",
"      not recommended",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Escitalopram crosses the placenta and is distributed into the amniotic fluid. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of escitalopram or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known. Escitalopram is the S-enantiomer of the racemic derivative citalopram; also refer to the Citalopram monograph.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of escitalopram may be altered. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1011736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased). Monitor for anxiety, social functioning, mania, panic attacks; akathisia. Monitor for signs and symptoms of serotonin syndrome or neuroleptic malignant syndrome-like reactions.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1011720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Escitalopram (the S-enantiomer of racemic citalopram) selectively inhibits the reuptake of serotonin in the presynaptic neuron and has minimal effects on norepinephrine or dopamine neuronal reuptake. Displays little to no affinity for serotonin, dopamine, adrenergic, histamine, GABA, or muscarinic receptor subtypes.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7689563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 8-12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1011722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2C19 and 3A4 to S-demethylcitalopram (S-DCT;",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      7",
"     </sub>",
"     the activity of escitalopram); S-DCT is metabolized to S-didemethylcitalopram (S-DDCT; active;",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      27",
"     </sub>",
"     the activity of escitalopram) via CYP2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80%; tablets and oral solution are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Mean:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 27-32 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Adults: 5 hours; Adolescents: 2.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (8% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance (citalopram):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic impairment: Decreased by 37%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate renal impairment: Decreased by 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): No information available",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1011739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/1/44053?source=see_link\">",
"      see \"Escitalopram: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of escitalopram. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, caffeine, CNS stimulants, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding); may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Some medicines should not be taken with escitalopram or should not be taken for a while after escitalopram has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. It may take up to 4 weeks to see therapeutic effects from this medication. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1011741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If used for an extended period of time, long-term usefulness of escitalopram should be periodically re-evaluated for the individual patient. A recent report describes 5 children (age: 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake, 2000).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Neonates born to women receiving SSRIs later during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isolan L, Pheula G, Salum GA Jr, et al, \"An Open-Label Trial of Escitalopram in Children and Adolescents With Social Anxiety Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2007, 17(6):751-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/18315447/pubmed\" id=\"18315447\" target=\"_blank\">",
"        18315447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, \"Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/10755580 /pubmed\" id=\"10755580 \" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murdoch D and Keam SJ, \"Escitalopram: A Review of Its Use in the Management of Major Depressive Disorder,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(16):2379-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/16266205/pubmed\" id=\"16266205\" target=\"_blank\">",
"        16266205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owley T, Walton L, Salt J, et al, \"An Open-Label Trial of Escitalopram in Pervasive Developmental Disorders,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005, 44(4):343-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/15782081/pubmed\" id=\"15782081\" target=\"_blank\">",
"        15782081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rao N, \"The Clinical Pharmacokinetics of Escitalopram,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2007, 46(4):281-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/17375980/pubmed\" id=\"17375980\" target=\"_blank\">",
"        17375980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, \"Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1-2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/16553536 /pubmed\" id=\"16553536 \" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, Jonas J, Findling RL, et al, \"A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(3):280-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/21/36184/abstract-text/16540812/pubmed\" id=\"16540812\" target=\"_blank\">",
"        16540812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13043 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36184=[""].join("\n");
var outline_f35_21_36184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13502640\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708748\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166813\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F608961\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011695\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011728\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166789\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166775\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874431\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011734\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011718\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011696\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052832\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166837\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011702\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689561\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011703\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166826\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166782\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011717\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166784\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166799\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011736\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011720\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689563\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011722\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011739\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011741\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=related_link\">",
"      Escitalopram: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/1/44053?source=related_link\">",
"      Escitalopram: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_21_36185="Continuous wave Doppler MS";
var content_f35_21_36185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52855%7ECARD%2F60384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52855%7ECARD%2F60384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 684px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler in mitral stenosis (MS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 664px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler obtained across the mitral orifice records a peak velocity of 1.7 m/s in this patient with rheumatic mitral stenosis (MS). Using the simplified Bernoulli formula, the initial diastolic gradient across the mitral valve is 12 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler in aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peak velocity, recorded by continuous wave Doppler obtained from the right upper sternal border, is 4.3 m/sec. By the Bernoulli equation, this represents a peak pressure across the valve of 74 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36185=[""].join("\n");
var outline_f35_21_36185=null;
var title_f35_21_36186="Prevention of venous thromboembolic disease in medical patients";
var content_f35_21_36186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of venous thromboembolic disease in medical patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Menaka Pai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     James D Douketis, MD, FRCPC, FACP, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/21/36186/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/21/36186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the 2003 nationwide inpatient sample from the Health Care Cost and Utilization Project in the United States, there were over 38 million hospital discharges in 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/1\">",
"     1",
"    </a>",
"    ]. Fifty-one percent of the more than 15 million medical patients discharged from hospital were estimated to be at risk for venous thromboembolism (VTE, ie, deep vein thrombosis [DVT]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary embolus [PE]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite significant advances in the prevention and treatment of VTE, pulmonary embolism remains the most common preventable cause of hospital death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/2-6\">",
"     2-6",
"    </a>",
"    ], being responsible for approximately 150,000 to 200,000 deaths per year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Thus, it is vital that efforts continue to be made to find means of preventing and managing VTE that are safer and more effective than those currently being used.",
"   </p>",
"   <p>",
"    Practical approaches to the prevention of VTE in medical patients will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/9\">",
"     9",
"    </a>",
"    ]. Approaches to the prevention of VTE in surgical patients and in patients with stroke are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed discussions about specific pharmacologic agents employed for VTE prevention are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROBLEM OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States there have been a number of initiatives aimed at calling attention to the prevalence of venous thromboembolism (VTE) and advocating for increasing the use of VTE prophylaxis in hospitalized patients. These initiatives have come from The National Quality Forum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/10\">",
"     10",
"    </a>",
"    ], The Surgical Care Improvement Project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/11\">",
"     11",
"    </a>",
"    ], the Centres for Medicine and Medicinal Services, the Joint Commission on Accreditation of Health Care Organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/12\">",
"     12",
"    </a>",
"    ], and the Office of the Surgeon General of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar initiatives have been developed in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/14\">",
"     14",
"    </a>",
"    ], the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], and Europe.",
"   </p>",
"   <p>",
"    The prevention of VTE is the number one strategy to improve patient safety in hospitals according to the Agency for Health Care Research and Quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, as part of the Surgical Care Improvement Project, the Center for Medicare and Medicaid Services (CMS) now considers appropriate VTE prophylaxis to be a pay-for-performance quality measure for specific surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is strong evidence from multiple randomized trials and analyses that appropriately employed thromboprophylaxis has a desirable benefit-to-risk ratio and is cost effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. Effective and safe prophylactic measures are now available for most high risk patients, and numerous evidence-based guidelines have been published for the prevention of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/23-25,28\">",
"     23-25,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prevention of VTE'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, while thromboprophylaxis has been shown to reduce the risk of VTE in hospitalized medical and surgical patients, and to reduce the risk of death in surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/20,29\">",
"     20,29",
"    </a>",
"    ], most studies and a meta-analysis have not been able to show a beneficial effect of thromboprophylaxis on reducing overall mortality in hospitalized medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/30-36\">",
"     30-36",
"    </a>",
"    ]. The reasons for this difference between medical and surgical patients are unclear but may be related to a greater number of comorbidities in medical patients that contribute to overall deaths. A large randomized trial assessing the use of graduated compression stockings (GCS) in medical patients, with or without low dose low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , found no added mortality benefit with the use of LMW heparin. This trial may have been underpowered to detect a significant difference in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the availability of these guidelines for the prevention of VTE and the availability of safe and effective prophylactic agents, numerous audits and reviews have demonstrated that appropriate thromboprophylaxis is not being offered to large numbers of patients, particularly those hospitalized with medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/37-47\">",
"     37-47",
"    </a>",
"    ]. Some of this reluctance is due to a fear of bleeding with the use of prophylactic anticoagulation on the part of both clinicians and patients, which is amplified by the lack of prospectively validated models for bleeding risk in medical patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Decision support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various strategies to improve the use of thromboprophylaxis have been demonstrated to be effective, including computerized order sets with electronic alerts, or pre-printed orders and quality improvement in the form of audit and feedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/48\">",
"     48",
"    </a>",
"    ]. Despite the existence of such programs, formal educational programs for involved health care professionals may still be needed in order to significantly improve the appropriate use of thromboprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Further efforts are required at improving the translation of data from clinical trials into clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/51-61\">",
"     51-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of appropriate prophylaxis, the incidence of venous thromboembolic disease (VTE, ie, pulmonary embolus [PE] and deep vein thrombosis [DVT]) has ranged from 10 to 80 percent in various hospitalized medical and surgical groups, where objective diagnostic screening tests have been used to detect asymptomatic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/23\">",
"     23",
"    </a>",
"    ]. By today's standards, all of these estimates are probably too high because of the increasing use of early ambulation and shorter lengths of hospitalization. Additionally, subclinical venous thromboemboli detected with screening tests do not necessarily translate into clinically meaningful events. However, data from audits and registries demonstrate that the incidence of VTE, and in particular fatal PE, remains excessively high in hospitalized patients.",
"   </p>",
"   <p>",
"    There are numerous risk factors for the development of VTE in medical patients, including previous VTE, cancer, immobility, and inherited or acquired hypercoagulable states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/62-77\">",
"     62-77",
"    </a>",
"    ]. Some of these are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Multiple acquired risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of VTE is increased in association with pregnancy, with the highest incidence being seen in the postpartum period, particularly in those undergoing caesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Overall, the risk of VTE in low risk pregnant women after 20 weeks is quite low (estimated as less than 1 per 3000) and approaches the background risk in nonpregnant women. Available data do not support routine anticoagulation of all pregnant women placed at bed rest, and routine antenatal prophylaxis for the pregnant medical patient is not recommended unless other risk factors for VTE are present. (See",
"    <a class=\"local\" href=\"#H5138262\">",
"     'VTE risk assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the presence of single or multiple thrombophilic factors (eg, marked obesity, prior episode of VTE) markedly increases the risk of VTE during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/77\">",
"     77",
"    </a>",
"    ]. The use of anticoagulation in such higher risk patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link&amp;anchor=H2#H2\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extended travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended travel, either by air or on land, appears to confer a small increased risk of VTE. The data supporting this association and possible preventive measures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=see_link&amp;anchor=H8#H8\">",
"     \"Patient assessment for air travel\", section on 'Deep vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high risk of developing VTE while hospitalized. Based upon a review of residents of Olmsted County for a period from 1980 through 1990, the age- and sex-adjusted incidence of VTE was more than 130 times greater among hospitalized patients than among community residents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/78\">",
"     78",
"    </a>",
"    ]. For both groups, the incidence of VTE increased with age and, with exception of women less than 40 years of age, was higher in hospitalized men than in women.",
"   </p>",
"   <p>",
"    Approximately one-half of community-based cases occurred in patients who developed VTE while residing in a nursing home or within 90 days of hospital discharge. The net result was that approximately 60 percent of all cases of VTE occurred in hospitalized, recently discharged, or nursing home patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autopsies demonstrate that death from an unexpected PE remains common and the majority of these occur in hospitalized medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. Without improvement in the use of VTE prophylaxis in medical patients, as has occurred in many intensive care unit patients, unexpected PE will remain a serious problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8747283\">",
"    <span class=\"h3\">",
"     Admission to intensive care units",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients admitted to intensive care units (ICUs) are considered high risk for VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/73,79-82\">",
"     73,79-82",
"    </a>",
"    ], even after routine prophylactic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This high risk was noted in a retrospective observational study of 175,665 critically ill adult patients admitted to 134 ICUs in Australia and New Zealand between 2006 and 2010. The crude ICU and hospital mortality rates in those who received early thromboprophylaxis were 6.3 and 10.6 percent, respectively. These rates were significantly lower than in those who did",
"    <strong>",
"     not",
"    </strong>",
"    receive thromboprophylaxis within 24 hours of ICU admission (7.6 and 11.2 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/84\">",
"     84",
"    </a>",
"    ]. The estimated attributable mortality effect of omitting early thromboprophylaxis was 3.9, 8.0, 15.4, and 9.4 percent for those with multiple trauma, sepsis, cardiac arrest, and pre-existing metastatic cancer, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=see_link&amp;anchor=H172458244#H172458244\">",
"     \"Overview of inpatient management in the adult trauma patient\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION OF VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overall approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to the prevention of fatal pulmonary embolism (PE):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prophylaxis &mdash; Primary prophylaxis is carried out using either drugs or physical methods that are effective for preventing deep vein thrombosis (DVT).",
"     </li>",
"     <li>",
"      Secondary prevention &mdash; Secondary prevention involves the early detection and treatment of subclinical venous thrombosis by screening medical patients with objective tests that are sensitive for the presence of DVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, no single screening method (eg, contrast venography, venous ultrasound, MRI venography) has found universal acceptance for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Accordingly, primary prophylaxis is preferred in most clinical circumstances; it is more cost effective than treatment of complications once they occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/87\">",
"     87",
"    </a>",
"    ]. Secondary prevention with screening is reserved for patients in whom primary prophylaxis is either contraindicated or shown to be ineffective.",
"   </p>",
"   <p>",
"    The characteristics of an ideal primary prophylactic method include ease of administration, effectiveness, safety (particularly with respect to bleeding), and cost-effectiveness or at least cost-neutrality when compared with current standards (",
"    <a class=\"graphic graphic_table graphicRef66235 \" href=\"mobipreview.htm?0/54/875\">",
"     table 1",
"    </a>",
"    ). The prophylactic measures currently available for hospitalized medical patients include low dose unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight (LMW) heparins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , intermittent pneumatic compression (IPC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graduated compression stockings (GCS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24\">",
"     24",
"    </a>",
"    ] and, where available, oral factor Xa or factor IIa (thrombin) inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Factor Xa inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5138262\">",
"    <span class=\"h2\">",
"     VTE risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with surgical patients, medical patients can be generally classified as being at low, moderate, or high risk for venous thromboembolism (VTE) depending upon their underlying medical condition and the presence of other comorbid factors. However, there is no",
"    <strong>",
"     formal",
"    </strong>",
"    , prospectively validated risk assessment model for medical patients that can be easily used by most clinicians to determine the need for anticoagulation in a specific patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Surgical risk groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon data from clinical trials for the prevention of VTE in medical patients, common conditions predisposing the patient for VTE include congestive heart failure, acute exacerbations of chronic pulmonary disease, stroke with lower limb paralysis, sepsis, and inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/16,30,51,71,79,80,88-100\">",
"     16,30,51,71,79,80,88-100",
"    </a>",
"    ]. Additional risk factors include known thrombophilia, prolonged immobility, age &gt;60 years, the presence of cancer, previous VTE, and admission to an intensive care unit. Many medical patients have multiple risk factors at the time of admission (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24,30,79,88-101\">",
"     24,30,79,88-101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Multiple acquired risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of empirically generated or data-derived risk models, based upon a number of the above-noted risk factors have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/102\">",
"     102",
"    </a>",
"    ]. Two of these are noted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"       Padua Prediction Score",
"      </strong>",
"      was used to determine VTE risk in 1180 consecutive medical patients. Patients were followed for up to 90 days following admission to assess the occurrence of symptomatic VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/51,103\">",
"       51,103",
"      </a>",
"      ]. The percent of subjects developing VTE was as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &ldquo;Low risk&rdquo; patients (711): 0.3 percent",
"     </li>",
"     <li>",
"      &ldquo;High risk&rdquo; patients receiving adequate in-hospital thromboprophylaxis (186): 2.2 percent",
"     </li>",
"     <li>",
"      &ldquo;High risk&rdquo; patients not receiving adequate in-hospital thromboprophylaxis (283): 11.0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"       IMPROVE risk score",
"      </strong>",
"      was used to determine VTE risk in 15,156 medical patients enrolled in the observational International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/101\">",
"       101",
"      </a>",
"      ]. The observed rate of VTE within 92 days of admission was 0.4 to 0.5 percent if none of these risk factors was present, and was in the range of 8 to 11 percent in those with the highest risk scores (",
"      <a class=\"external\" href=\"file://www.outcomes-umassmed.org/IMPROVE/risk_score/vte/index.html\">",
"       IMPROVE thrombosis risk model",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These prediction scores require validation from independent, prospective studies before they can be used in routine practice. However, despite the absence of a prospectively validated risk model, the following conclusions can be reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, VTE prophylaxis should be considered in medical patients older than age 40 who have limited mobility for &ge;3 days, and have at least one thrombotic risk factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/9,88\">",
"       9,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All patients admitted to intensive care units are considered high risk for VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/73,79-82\">",
"       73,79-82",
"      </a>",
"      ], even after routine prophylactic anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/83\">",
"       83",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=see_link&amp;anchor=H172458244#H172458244\">",
"       \"Overview of inpatient management in the adult trauma patient\", section on 'Thromboprophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23758764\">",
"    <span class=\"h2\">",
"     Bleeding risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospectively validated models for evaluating the risk of bleeding in hospitalized medical patients, which makes it difficult for the clinician to fully assess the risks and benefits of prophylactic anticoagulation in this group of patients. Retrospective analysis of data from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) has been used to assess in-hospital bleeding incidence in 15,156 medical patients and to identify risk factors at the time of admission associated with in-hospital bleeding risk in acutely ill medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/104\">",
"     104",
"    </a>",
"    ]. Findings of this study include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative incidence of major and non-major in-hospital bleeding within 14 days of admission was 3.2 percent. Active gastroduodenal ulcer (OR 4.15; 95% CI 2.21-7.77), bleeding within the three months prior to admission (OR 3.64; 95% CI 2.21-5.99), and a platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      (OR 3.37; 95% CI 1.84-6.18) were the strongest independent risk factors for bleeding at the time of admission.",
"     </li>",
"     <li>",
"      Other bleeding risk factors included increased age, hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal failure, intensive care unit stay, presence of a central venous catheter, rheumatic disease, cancer, and male sex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of the above risk factors, with appropriate weighting, was entered into a risk model (",
"    <a class=\"external\" href=\"file://www.outcomes-umassmed.org/IMPROVE/risk_score/bleeding/index.html\">",
"     IMPROVE Bleeding risk model",
"    </a>",
"    ) with scores ranging from zero to 15. Those with risk scores of 1, 4, 7, 10, and 15 had observed rates of clinically important bleeding of 0.5, 1.6, 4.1, 9.7, and 14.0 percent, respectively. If this model is validated in other patient populations, it may assist clinicians in estimating the risks of prophylactic anticoagulation in patients at risk for VTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5137505\">",
"    <span class=\"h2\">",
"     Values and preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of values and preferences in relation to the use of anticoagulants was first introduced in the 2004 American College of Chest Physicians (ACCP) Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/54\">",
"     54",
"    </a>",
"    ]. The decision to use (or not use) prophylactic anticoagulation should be discussed by the clinician and the patient.",
"   </p>",
"   <p>",
"    As general examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the treatment of established PE, a greater value is normally placed on the prevention of death from recurrent PE than from the relatively low risk of bleeding from the use of anticoagulation.",
"     </li>",
"     <li>",
"      In orthopedic surgery, greater value is placed on the avoidance of bleeding from anticoagulation over the relatively low frequency of death from PE if thromboprophylaxis is not used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more specific example concerning the use (or non-use) of prophylactic anticoagulation in an older patient with atrial fibrillation is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link&amp;anchor=H20187974#H20187974\">",
"     \"Anticoagulation in older adults\", section on 'Values and preferences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5139523\">",
"    <span class=\"h2\">",
"     Making the decision",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the individual medical patient there will be an uncertain balance between the risk of VTE if anticoagulation is not employed and the risk of major or clinically important bleeding if anticoagulation is employed. Current evidence is insufficient to recommend a validated tool for weighing these risks and benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5138262\">",
"     'VTE risk assessment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23758764\">",
"     'Bleeding risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While UpToDate does not endorse any of the current risk models, an admittedly imperfect example of how the prudent clinician might approach this issue can be taken from the IMPROVE risk models described above for the three following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 35-year-old man is admitted to the hospital for management of hepatic failure. He has a history of gastrointestinal bleeding within the past three months, no prior VTE, thrombophilia, or malignancy, and his admission platelet count is",
"      <span class=\"nowrap\">",
"       40,000/microL.",
"      </span>",
"      According to the IMPROVE risk models, his risk of VTE from the time of hospital admission to 90 days post hospital discharge is 0.5 percent and his risks of major and clinically important bleeding are &gt;7 and &gt;14 percent, respectively. Prophylactic anticoagulation would",
"      <strong>",
"       not",
"      </strong>",
"      be appropriate for this individual, while mechanical means of prophylaxis might be considered.",
"     </li>",
"     <li>",
"      A 65-year-old woman is admitted to the hospital for treatment of an active malignancy. She has a history of prior VTE but no history of bleeding, hepatic, or renal failure. Her platelet count is",
"      <span class=\"nowrap\">",
"       150,000/microL.",
"      </span>",
"      According to the IMPROVE risk models, her risk of VTE is 11.0 percent, and her risks of major and clinically important bleeding are 0.3 and 1.6 percent, respectively. Prophylactic anticoagulation would be appropriate for this woman.",
"     </li>",
"     <li>",
"      An 86-year-old man is admitted to the hospital for treatment of community-acquired pneumonia. He has a history of a duodenal ulcer which has not bled in the past two years. He also has a history of an episode of VTE five years ago at which time he was found to be a heterozygous carrier of the factor V Leiden mutation. He has a moderate degree of renal insufficiency, with an estimated glomerular filtration rate of 45",
"      <span class=\"nowrap\">",
"       mL/min/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      According to the IMPROVE risk models, his 90-day risk of VTE is 11 percent and his risks of major and clinically important bleeding are 4.6 and 9.7 percent, respectively. As the risks of both bleeding and thrombosis are high in this patient, a decision to employ or not employ prophylactic anticoagulation will depend upon the clinician&rsquo;s clinical judgment as well as input concerning the patient&rsquo;s values and preferences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS FOR VTE PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5137695\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hospitalized and immobilized medical patients, unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH), low molecular weight (LMW) heparin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    have all been shown to be superior to placebo in preventing venous thromboembolism (VTE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/93-95,106-108\">",
"     93-95,106-108",
"    </a>",
"    ]. In a meta-analysis of 36 randomized trials comparing the ability of the various pharmacological agents to prevent VTE, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, UFH was associated with a significantly reduced risk of deep venous thrombosis (DVT) (risk ratio [RR] 0.33; 95% CI 0.26-0.42) and pulmonary embolism (PE) (RR 0.64; 95% CI 0.50-0.82), as was LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (RR 0.56; 95% CI 0.45-0.70 and RR 0.37; 95% CI 0.21-0.64, respectively).",
"     </li>",
"     <li>",
"      When compared with placebo, UFH given in a dose of 5000 units three times daily (RR 0.27; 95% CI 0.20-0.36) was significantly more effective in preventing DVT than UFH given in a dose of 5000 units twice daily (RR 0.52; 95% CI 0.28-0.96). Neither UFH nor LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      reduced mortality.",
"     </li>",
"     <li>",
"      When directly compared with UFH, LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was associated with a significantly lower risk of DVT (RR 0.68; 95% CI 0.52-0.88) and injection site hematoma (RR 0.47; 95% C, 0.36-0.62), but no difference was seen between the two agents in the risk of bleeding or thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that both UFH and LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    reduced venous thromboembolic risk in hospitalized medical patients, but that neither agent altered mortality. When directly compared, LMW heparin was more effective in preventing DVT than was UFH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/44,94,106,109,110\">",
"     44,94,106,109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in patients suffering ischemic stroke with leg paralysis, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was either superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/99,111\">",
"     99,111",
"    </a>",
"    ] or non-inferior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/112\">",
"     112",
"    </a>",
"    ] to UFH in the prevention of VTE. A meta-analysis of all three studies indicated that the use of LMW heparin, when compared with UFH, was associated with a significantly greater risk reduction for any VTE (odds ratio 0.54; 95% CI 0.41-0.70), with no significant increase in clinically relevant bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision analytic model compared the prophylactic use of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in critically ill patients with weekly compression ultrasound screening for DVT, and concluded that such prophylactic anticoagulation provided better value in terms of costs and health care gains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter trial in critically ill patients (the PROTECT trial),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    5000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    was not superior to unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (5000 units twice daily) in the prevention of proximal DVT, but the incidence of PE was significantly reduced in the dalteparin-treated group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/115\">",
"     115",
"    </a>",
"    ]. The incidence of major bleeding and of death was similar in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5137702\">",
"    <span class=\"h2\">",
"     Extended duration prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended duration prophylactic anticoagulation (eg, four weeks) has been shown to significantly reduce the incidence of VTE compared with a standard regimen (eg, one week) in high-risk",
"    <strong>",
"     surgical",
"    </strong>",
"    patients. Three randomized studies have assessed the efficacy and safety of extended duration prophylactic anticoagulation in acutely ill",
"    <strong>",
"     medical",
"    </strong>",
"    patients, and are described below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Extended prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first was a large randomized placebo-controlled study in patients with reduced mobility who were hospitalized for an acute medical illness. Subjects were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    subcutaneously) or placebo for approximately 28 days after having received open label enoxaparin for an initial 10 days (the EXCLAIM Study). Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While extended-duration",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      significantly reduced the incidence of VTE compared with placebo (2.5 versus 4.0 percent), it also significantly increased major bleeding events (0.8 versus 0.3 percent).",
"     </li>",
"     <li>",
"      On sub-group analysis, the benefits of extended-duration",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      were restricted to women, subjects &gt;75 years of age, and those with recently reduced mobility (ie, bed rest or sedentary without bathroom privileges).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second study compared 6 to 14 days of VTE prophylaxis with the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40 mg once daily) versus extended prophylaxis for 30 days with the orally active direct factor Xa inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    (2.5 mg twice daily) in acutely ill medical patients with congestive failure, respiratory failure, or other medical disorders and at least one other risk factor for VTE who were hospitalized with an expected stay of &ge;3 days. Results of this double-blind, double-dummy, placebo-controlled trial (the ADOPT trial: Apixaban dosing to optimize protection from thrombosis) in 4495 evaluable subjects included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/116\">",
"     116",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary efficacy outcome (30-day composite of death related to VTE, PE, symptomatic DVT, or asymptomatic proximal leg DVT detected on bilateral compression ultrasonography on day 30) was not significantly different between the two study arms (2.71 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      versus 3.06 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , relative risk for apixaban 0.87; 95% CI 0.62-1.23).",
"     </li>",
"     <li>",
"      By day 30, major bleeding, the primary safety outcome, had occurred significantly more often in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      -treated group (0.47 versus 0.19 percent; relative risk for apixaban 2.58; 95% CI 1.02-7.24).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The third trial compared 10 days of VTE prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40 mg once daily) followed by a placebo versus extended prophylaxis for 35 &plusmn; 4 days with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    (10 mg once daily) in 8101 patients &ge;40 years of age who were hospitalized for an acute medical illness (the MAGELLAN Study). Results of this randomized, double-blind trial included the following at day 10 (noninferiority test) and day 35 (superiority test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/117\">",
"     117",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 10 days, a primary efficacy outcome event (the composite of asymptomatic proximal DVT or symptomatic VTE) occurred in 2.7 percent of those receiving either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (relative risk with rivaroxaban 0.97; 95% CI 0.71-1.31). A principal safety outcome event (the composite of major or clinically relevant nonmajor bleeding) occurred significantly more often in the rivaroxaban-treated group (2.8 versus 1.2 percent of those in the enoxaparin-treated group).",
"     </li>",
"     <li>",
"      At 35 days, a primary efficacy outcome event occurred significantly less often in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      -treated group (4.4 percent) than in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      -placebo treated group (5.7 percent; relative risk with rivaroxaban 0.77; 95% CI 0.62-0.96), while a principal safety outcome event occurred significantly more often in the rivaroxaban-treated group (4.1 versus 1.7 percent of those in the enoxaparin-placebo treated group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While final analysis of the above trials may help to determine the relative risks and benefits of extended duration prophylaxis in medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/118\">",
"     118",
"    </a>",
"    ], a meta-analysis that included results of the EXCLAIM, ADOPT, and MAGELLAN studies has concluded that routine administration of post-discharge prophylaxis is not likely to be beneficial to the patients admitted for medical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/119\">",
"     119",
"    </a>",
"    ]. Further research is required to determine if post-discharge prophylaxis significantly reduces clinically meaningful outcomes (as opposed to composite outcomes that include asymptomatic VTE), and if so, whether the additional bleeding risk incurred is acceptable to patients and clinicians. Selective administration of post-discharge prophylaxis to patients at highest risk of symptomatic VTE, using agents with a reasonable safety profile, may yield greatest benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Heparins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of trials determining the effectiveness and safety of unfractionated or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    versus either placebo or no treatment for the prevention of VTE in general medical patients, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/120\">",
"     120",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant risk reduction in DVT by 60 percent (relative risk 0.40; 95% CI 0.31-0.53) and PE by 42 percent (RR 0.58; 95% CI 0.43-0.80) with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparations compared with placebo or no treatment.",
"     </li>",
"     <li>",
"      Treatment with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparations resulted in a significant increase in major hemorrhage (RR 2.18; 95% CI 1.28-3.72) and minor hemorrhage (RR 1.74; 95% CI 1.26-2.41) when compared with placebo or no treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Low dose unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 12 randomized studies of UFH given either two (BID) or three (TID) times daily for the prevention of VTE in medical patients, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/121\">",
"     121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the overall rate of VTE between BID",
"      <span class=\"nowrap\">",
"       (5.4/1000",
"      </span>",
"      patient-days) and TID",
"      <span class=\"nowrap\">",
"       (3.5/1000",
"      </span>",
"      patient-days) UFH",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      dosing. TID heparin showed a trend toward a decrease in PE (BID",
"      <span class=\"nowrap\">",
"       1.5/1000",
"      </span>",
"      patient-days, TID",
"      <span class=\"nowrap\">",
"       0.5/100",
"      </span>",
"      patient-days) and in proximal DVT plus PE (BID",
"      <span class=\"nowrap\">",
"       2.3/1000",
"      </span>",
"      patient-days, TID",
"      <span class=\"nowrap\">",
"       0.9/1000",
"      </span>",
"      patient-days).",
"     </li>",
"     <li>",
"      The risk for major bleeding was significantly greater with TID than with BID UFH dosing (BID",
"      <span class=\"nowrap\">",
"       0.35/1000",
"      </span>",
"      patient-days, TID",
"      <span class=\"nowrap\">",
"       0.96/1000",
"      </span>",
"      patient-days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a second meta-analysis involving 16 studies found no difference between BID and TID UFH dosing in the relative risks for DVT, PE, death, or major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its relatively low side effect profile, low dose UFH has the advantages of being relatively inexpensive and easily administered. Anticoagulant monitoring is also not required. However, the platelet count should be monitored regularly in all patients receiving low dose UFH to detect the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Platelet count monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations are available. These drugs have the advantage that they can be given subcutaneously once or twice daily at a constant dose without laboratory monitoring. In addition, there is a lower incidence of heparin-induced thrombocytopenia than with UFH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link&amp;anchor=H8#H8\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Unfractionated versus LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two meta-analyses of randomized trials comparing the use of UFH versus LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for the prevention of VTE in medical patients, there was no statistically significant difference in efficacy between the two types of heparin preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/120,122\">",
"     120,122",
"    </a>",
"    ]. However, the earlier meta-analysis found a significant 72 percent risk reduction in major bleeding when LMW heparin was compared with UFH (RR 0.28; 95% CI 0.10-0.78), which was not found in the later meta-analysis, although the 95 percent confidence limits for these comparisons were quite wide.",
"   </p>",
"   <p>",
"    As a result of these studies in hospitalized medical patients as well as in those involving patients with ischemic stroke and leg paralysis, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been considered the prophylactic agent of choice for preventing VTE in high risk medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/30,79,89-100,107,111-113\">",
"     30,79,89-100,107,111-113",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prevention of VTE'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is discussed elsewhere in UpToDate, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using the composite end point of asymptomatic or symptomatic DVT and non-fatal or fatal PE,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    was compared with placebo for 6 to 14 days in 644 hospitalized medical patients. VTE was detected in 5.6 percent of patients treated with fondaparinux versus 10.5 percent of patients given placebo, for a relative risk reduction of 47 percent (95% Cl 7.7-69) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in recommended doses has shown lesser efficacy than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    30 mg twice daily, the enoxaparin regimen used in North America. Fondaparinux in recommended doses appears to have the same efficacy as enoxaparin 40 mg once daily, the enoxaparin regimen favored in Europe.",
"   </p>",
"   <p>",
"    A 50 percent reduction in the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    has been suggested for thromboprophylaxis in those with reduced renal function (ie, creatinine clearances in the range of 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/125\">",
"     125",
"    </a>",
"    ]. The safety and efficacy of reduced dosing was tested in a multicenter prospective cohort study in 206 acutely ill older medical patients (mean age 82 years; mean creatinine clearance 33",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    [range 20 to 50]) at high risk for both bleeding and thrombosis. Subjects received 1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of fondaparinux for 6 to 15 days as thromboprophylaxis. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/126\">",
"     126",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Major bleeding occurred in one subject (0.49 percent)",
"     </li>",
"     <li>",
"      Clinically relevant non-major bleeding occurred in eight subjects (3.88 percent)",
"     </li>",
"     <li>",
"      Symptomatic VTE developed in three subjects (1.46 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , with or without other antiplatelet drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), is highly effective in reducing major",
"    <strong>",
"     arterial",
"    </strong>",
"    thrombotic events in patients who are at risk or who have established atherosclerotic disease. However, there is little evidence that aspirin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clopidogrel have a significant effect on the prevention of",
"    <strong>",
"     venous",
"    </strong>",
"    thromboembolic events in medical patients.",
"   </p>",
"   <p>",
"    An early meta-analysis and a later literature review indicated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduced the incidence of VTE by approximately 20 percent compared with placebo or no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. However, other studies have shown either no significant benefit or inferiority when compared with other modalities such as LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/128\">",
"     128",
"    </a>",
"    ]. As a result, the 2012 ACCP Guidelines do not recommend the use of aspirin, either alone or in combination, as prophylaxis against VTE in any medical patient group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is not an appropriate agent for immediate and short-term prevention of VTE in medical patients for two reasons (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use of warfarin\", section on 'Mechanism of action'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ultimate anticoagulant effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is delayed, and does not occur until 36 to 72 hours after drug administration.",
"     </li>",
"     <li>",
"      Achieving targeted levels of anticoagulation may be problematic because hospitalized medical patients may have comorbidities (eg, impaired liver function), and may be receiving medications that interact with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (eg, antibiotics) and may lead to supratherapeutic anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MECHANICAL METHODS OF THROMBOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical methods for the prevention of venous thromboembolism (VTE) are primarily indicated in patients at high risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. They are also used in patients because of the presence of a bleeding lesion such as peptic ulcer or intracranial hemorrhage.",
"   </p>",
"   <p>",
"    When used in all of these circumstances, it is recommended that consideration be given to transition to a pharmacologic agent as soon as the bleeding risk becomes acceptably low or has been reversed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intermittent pneumatic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent pneumatic compression (IPC) prevents deep vein thrombosis (DVT) by enhancing blood flow in the deep veins of the legs, thereby preventing venous stasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/129\">",
"     129",
"    </a>",
"    ]. IPC also reduces plasminogen activator inhibitor-1 (PAI-1), thereby increasing endogenous fibrinolytic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/130\">",
"     130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28297?source=see_link&amp;anchor=H8#H8\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\", section on 'Plasminogen activator inhibitor-1'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link&amp;anchor=H6#H6\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Plasminogen activator inhibitor-1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IPC devices are an alternative for VTE prevention in patients with a high risk of bleeding in whom anticoagulant drugs are contraindicated. There are no data available on skin complications of IPC use; however, skin breakdown is a plausible side effect, especially in the frail older adult population. IPC devices are also contraindicated in patients with evidence of leg ischemia due to peripheral vascular disease. There are no published studies of IPC devices in hospitalized medical patients, though data are available from studies of surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/131\">",
"     131",
"    </a>",
"    ]. A meta-analysis has shown that compared with IPC, the combined use of IPC and a pharmacologic agent was more effective in reducing the overall incidence of VTE, particularly the incidence of DVT in surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/131\">",
"     131",
"    </a>",
"    ]. The 2012 ACCP guidelines summarized this indirect data, and support the use of IPC to prevent thrombosis in patients at high risk for bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/28\">",
"     28",
"    </a>",
"    ]. Attention must be paid to optimal compliance, as well as proper fit of the IPC device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H26#H26\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Mechanical methods of thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Graduated compression stockings and venous foot pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less convincing evidence regarding the efficacy of graduated compression stockings (GCS) and venous foot pump (VFP) in randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis, GCS was found to be ineffective in the prevention of VTE in patients with ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/133\">",
"     133",
"    </a>",
"    ]. One randomized trial showed that thigh-length GCS was associated with no benefit with respect to reduction of VTE, along with a fourfold increase in skin ulcers and necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/134\">",
"     134",
"    </a>",
"    ]. Similarly, there are few convincing studies showing the efficacy of VFP devices.",
"   </p>",
"   <p>",
"    The 2012 ACCP Guidelines suggest the use of either IPC or GCS rather than no mechanical prophylaxis in acutely ill hospitalized medical patients at increased risk for thrombosis who are bleeding or are at high risk for major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of graduated compression stockings to prevent VTE following stroke is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H90846504#H90846504\">",
"     \"Medical complications of stroke\", section on 'Graduated compression stockings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H90846716#H90846716\">",
"     \"Medical complications of stroke\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     VTE PREVENTION IN HEALTHY SUBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few prospective, randomized studies of the prevention of venous thromboembolism (VTE) in otherwise healthy subjects. Two of these are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have suggested that the use of statins significantly reduced the incidence of VTE in subjects with no history of cardiovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    no VTE risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/135-138\">",
"     135-138",
"    </a>",
"    ], as well as in those with a past history of atherothrombotic disease or malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/139-143\">",
"     139-143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The JUPITER study was a randomized, double-blind, placebo-controlled, multicenter trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    in the primary prevention of cardiovascular disease in men &ge;50 years of age and women &ge;60 years of age with no history of cardiovascular disease, a low-density lipoprotein (LDL) cholesterol level &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and a high-sensitivity C-reactive protein level of &ge;2.0",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    VTE was a pre-specified outcome of JUPITER. In this study, 17,802 apparently healthy subjects were randomly assigned in a 1:1 ratio to treatment with oral rosuvastatin (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or a matching placebo. At a median follow-up of 1.9 years (maximum: five years), the following results were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/136\">",
"     136",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic VTE occurred in 94 participants: 34 in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      group and 60 in the placebo group, for VTE rates of 0.18 and 0.32",
"      <span class=\"nowrap\">",
"       events/100",
"      </span>",
"      person-years of follow-up, respectively (hazard ratio with rosuvastatin 0.57; 95% CI 0.37-0.86).",
"     </li>",
"     <li>",
"      Hazard ratios for the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      for unprovoked VTE, provoked VTE, pulmonary embolism, and deep vein thrombosis were similarly significant at 0.61, 0.52, 0.77, and 0.45, respectively. The use of rosuvastatin significantly reduced the composite end point of first cardiovascular event, VTE, or death (hazard ratio 0.66; 95% CI 0.57-0.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a meta-analysis of 29 published and unpublished randomized clinical trials on this subject concluded that allocation to statin therapy did not significantly reduce the risk of VTE events (OR 0.89; 95% CI 0.78-1.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/144\">",
"     144",
"    </a>",
"    ]. Exclusion of the JUPITER trial results did not materially alter this conclusion (OR 0.93; 94% CI 0.82-1.07).",
"   </p>",
"   <p>",
"    These conflicting observations on the potential value of statins in reducing the incidence of VTE",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    preventing VTE recurrence will require confirmation via prospective randomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to significantly reduce the occurrence of VTE in women with few or no risk factors for VTE was demonstrated in the Women's Health Study, in which VTE rates were measured in 39,876 female health professionals randomly assigned to receive either low-dose aspirin (100 mg orally every other day) or placebo for 10 years in a double-blind fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/146\">",
"     146",
"    </a>",
"    ]. Results of this study included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of VTE was similar in both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      - and placebo-treated subjects (1.18 versus 1.25 events per 1000 patient-years, respectively; relative hazard 0.95; 95% CI 0.79-1.13).",
"     </li>",
"     <li>",
"      On subgroup analysis, no VTE risk factor (ie, age, obesity, menopausal status, reported VTE at baseline, factor V Leiden, prothrombin gene mutation) modified the relationship between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and the overall hazard of VTE.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with a significantly increased risk of gastrointestinal bleeding, peptic ulcer, hematuria, bruising, and epistaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based case control study, an analysis restricted to persons without a history of cardiovascular events indicated that the current use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    did not significantly reduce the incidence of VTE (adjusted relative risk 0.98; 95% CI 0.86-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Group versus individual recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous attempts have been made to develop risk assessment models for venous thromboembolism (VTE) in hospitalized medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/62,63,66,68,71-74\">",
"     62,63,66,68,71-74",
"    </a>",
"    ]. At this time, none has been validated in prospective trials, although such studies are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24\">",
"     24",
"    </a>",
"    ]. Since clinical trials for the prevention of VTE have been successfully carried out only in specific GROUPS of patients, current recommendations are therefore group specific.",
"   </p>",
"   <p>",
"    Accordingly, recommendations for prevention of VTE are best made in a group-specific fashion with one very important caveat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/54\">",
"     54",
"    </a>",
"    ]. In patients with additional risk factors (eg, previous VTE, advanced age [particularly &gt;75 years], active cancer or a history of cancer) consideration should be given to more aggressive prophylaxis in the form of increased intensity or duration of a pharmacologic agent, or the addition of a mechanical device such as IPC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24,147\">",
"     24,147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Patients at high risk of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;For medical patients at high risk of bleeding from the use of an anticoagulant, mechanical thromboprophylaxis (ie, intermittent pneumatic compression [IPC] or graduated compression stockings [GCS]) should be used. If or when the high risk of bleeding has decreased, pharmacologic agents should be started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Neuraxial anesthesia or analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients undergoing neuraxial anaesthesia or analgesia are at risk for spinal or epidural bleeding when receiving anticoagulant thromboprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/148\">",
"     148",
"    </a>",
"    ]. Careful patient selection and caution are recommended with the use of antithrombotic agents in this setting. The recommendations of the American Society of Regional Anaesthesia and Pain Medicine should be followed, and are available on its website at",
"    <a class=\"external\" href=\"file://www.asra.com/\">",
"     www.asra.com",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/149\">",
"     149",
"    </a>",
"    ]. The same recommendations apply for patients receiving deep peripheral nerve blocks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful attention should be paid to renal function throughout the use of most anticoagulants. Those patients receiving low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , or any antithrombotic agents primarily cleared by the kidneys, elderly patients, and those with diabetes mellitus or at high risk of bleeding require special attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24\">",
"     24",
"    </a>",
"    ]. This may require a decrease in the usual dose of the drug or use of an alternative form of thromboprophylaxis. In all cases, the manufacturer's suggested dosage guidelines in the presence of renal impairment should be followed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H39#H39\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Medical center policies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every hospital should develop a formal active strategy for the prevention of VTE. This should be in the form of a written institution-wide thromboprophylaxis policy endorsed by department heads and medical advisory boards. Strategies should be developed to increase compliance with appropriate use of thromboprophylaxis in at-risk patients, including the use of computerized order sets and prompts, pre-printed orders, and periodic audit, including follow-up with feedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24,150\">",
"     24,150",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Problem overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The article \"Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (9th Edition)\" is an extensively referenced guideline for the prevention of VTE, which may be useful in formulating these policies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/21/36186/abstract/28\">",
"     28",
"    </a>",
"    ]. Their grading system is identical to that used in UpToDate, and includes both the strength of the recommendation as well as the quality of the available evidence. The concept of values and preferences has also been incorporated into a number of these recommendations. (See",
"    <a class=\"local\" href=\"#H5137505\">",
"     'Values and preferences'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Assignment of risk group",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no formal, prospectively validated risk assessment model for medical patients. However, common conditions predisposing the patient for VTE include congestive failure, acute exacerbations of chronic pulmonary disease, stroke with paralysis, sepsis, inflammatory bowel disease, a high degree of immobility, age &gt;75 years, and the presence of cancer or a previous episode of VTE. (See",
"    <a class=\"local\" href=\"#H5138262\">",
"     'VTE risk assessment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32\">",
"     'Group versus individual recommendations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, VTE prophylaxis is considered reasonable for medical patients older than age 40 who have limited mobility for &ge;3 days, and have at least one thrombotic risk factor as listed above. All patients admitted to intensive care units are considered high risk for VTE and will require some form of thromboprophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Specific recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For hospitalized medical patients without obvious risk factors for VTE, we suggest that anticoagulation not be employed (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Options for this low risk group include early ambulation with or without mechanical methods of thromboprophylaxis.",
"     </li>",
"     <li>",
"      For most patients who are hospitalized with an acute medical illness, have at least one risk factor for VTE, and do not have an increased risk of bleeding, we recommend the use of prophylactic anticoagulation over mechanical methods (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Assignment of risk group'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Available choices for acutely ill medical patients include LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , low dose unfractionated heparin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      at doses recommended by the manufacturer. We suggest either LMW heparin or unfractionated heparin over fondaparinux for non-critically ill medical patients at moderate risk for VTE, and LMW heparin over unfractionated heparin or fondaparinux in critically ill patients at higher risk for VTE (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Unfractionated versus LMW heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VTE prophylaxis should typically continue until the patient is discharged from the hospital. We suggest against extending the duration of thromboprophylaxis beyond the period of the acute hospital stay (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with risk factors for VTE for whom there is a contraindication to anticoagulant thromboprophylaxis, we suggest the optimal use of mechanical methods of thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We suggest starting a pharmacologic agent (eg, LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ) as soon as the bleeding risk becomes acceptably low or when the bleeding lesion or bleeding risk has been reversed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prevention of VTE following stroke is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3024506\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Graham F Pineo, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/1\">",
"      Anderson FA Jr, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/2\">",
"      Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991; 78:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/3\">",
"      Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/4\">",
"      White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/5\">",
"      Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/6\">",
"      Martino MA, Borges E, Williamson E, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006; 107:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/7\">",
"      Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. JAMA 1986; 255:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/8\">",
"      Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/9\">",
"      Dobromirski M, Cohen AT. How I manage venous thromboembolism risk in hospitalized medical patients. Blood 2012; 120:1562.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.qualityforum.org/Projects/s-z/VTE_Phase_I/Venous_Thromboembolism_(VTE)_I.aspx (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     Surgical Care Improvement Project (SCIP) file://www.jointcommission.org/surgical_care_improvement_project/ (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services and Joint Commission on Accreditation of Health Care Organizations file://www.hhs.gov/ and file://www.jointcommission.org/ (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/13\">",
"      Rathbun S. Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation 2009; 119:e480.",
"     </a>",
"    </li>",
"    <li>",
"     Safer Healthcare Now www.saferhealthcarenow.ca (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE clinical guideline. file://www.nice.org.uk/CG092 (Accessed on June 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/16\">",
"      Hill J, Treasure T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ 2010; 340:c95.",
"     </a>",
"    </li>",
"    <li>",
"     Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality. Available at www.ahrq.gov/clinic/pt-safety/. Accessed January 3, 2002.",
"    </li>",
"    <li>",
"     Specifications Manual for National Hospital Inpatient Quality Measures www.qualitynet.org (Accessed on March 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/19\">",
"      Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/20\">",
"      Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/21\">",
"      Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/22\">",
"      Nurmohamed MT, Rosendaal FR, B&uuml;ller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/23\">",
"      Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/24\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/25\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/26\">",
"      Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients. A decision analysis and economic evaluation. Am J Resp Crit Care Med 2011; 184:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/27\">",
"      Thirugnanam S, Pinto R, Cook DJ, et al. Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care 2012; 16:R43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/28\">",
"      Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/29\">",
"      Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 2:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/30\">",
"      Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/31\">",
"      Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/32\">",
"      Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/33\">",
"      G&auml;rdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/34\">",
"      Mah&eacute; I, Bergmann JF, d'Az&eacute;mar P, et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol 2005; 61:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/35\">",
"      Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/36\">",
"      Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/37\">",
"      Kucher N, Tapson VF, Goldhaber SZ, DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/38\">",
"      Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/39\">",
"      Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005; 165:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/40\">",
"      Rahme E, Dasgupta K, Burman M, et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ 2008; 178:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/41\">",
"      Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/42\">",
"      Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/43\">",
"      Cohn SL. Prophylaxis of venous thromboembolism in the US: improving hospital performance. J Thromb Haemost 2009; 7:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/44\">",
"      Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med 2009; 122:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/45\">",
"      Bergmann JF, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost 2010; 103:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/46\">",
"      Mokhtari M, Salameh P, Kouchek M, et al. The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. J Thromb Haemost 2011; 9:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/47\">",
"      Pendergraft T, Liu X, Edelsberg J, et al. Prophylaxis against venous thromboembolism in hospitalized medically ill patients. Circ Cardiovasc Qual Outcomes 2013; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/48\">",
"      Mahan CE, Spyropoulos AC. Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (Minneap) 2010; 38:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/49\">",
"      Bagot C, Gohil S, Perrott R, et al. The use of an exclusion-based risk-assessment model for venous thrombosis improves uptake of appropriate thromboprophylaxis in hospitalized medical patients. QJM 2010; 103:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/50\">",
"      Lawall H, Matthiessen A, Hohmann V, et al. Venous thromboembolism in medical outpatients - a cross-sectional survey of risk assessment and prophylaxis. Thromb Haemost 2011; 105:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/51\">",
"      Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/52\">",
"      Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005; 241:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/53\">",
"      Stinnett JM, Pendleton R, Skordos L, et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/54\">",
"      Sch&uuml;nemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:688S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/55\">",
"      Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/56\">",
"      Piazza G, Rosenbaum EJ, Pendergast W, et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation 2009; 119:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/57\">",
"      Piazza G, Goldhaber SZ. Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond. Circulation 2009; 120:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/58\">",
"      Kucher N, Puck M, Blaser J, et al. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost 2009; 7:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/59\">",
"      Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost 2009; 102:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/60\">",
"      Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 2009; 102:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/61\">",
"      Baglin T. Defining the population in need of thromboprophylaxis - making hospitals safer. Br J Haematol 2010; 149:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/62\">",
"      Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/63\">",
"      Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008; 141:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/64\">",
"      Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001; 38:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/65\">",
"      Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/66\">",
"      Haas SK, Hach-Wunderle V, Mader FH, et al. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clin Appl Thromb Hemost 2007; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/67\">",
"      Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:I9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/68\">",
"      Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/69\">",
"      Memtsoudis SG, Della Valle AG, Besculides MC, et al. Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges. J Arthroplasty 2010; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/70\">",
"      Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/71\">",
"      Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost 2006; 4:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/72\">",
"      Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/73\">",
"      Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/74\">",
"      Samama MM, Dahl OE, Quinlan DJ, et al. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 2003; 88:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/75\">",
"      Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol 2008; 15:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/76\">",
"      McColl MD, Walker ID, Greer IA. Risk factors for venous thromboembolism in pregnancy. Curr Opin Pulm Med 1999; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/77\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/78\">",
"      Heit JA, Melton LJ 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/79\">",
"      Khouli H, Shapiro J, Pham VP, et al. Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 2006; 21:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/80\">",
"      Laporte S, Mismetti P. Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model. Crit Care Med 2010; 38:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/81\">",
"      Ortel TL. Acquired thrombotic risk factors in the critical care setting. Crit Care Med 2010; 38:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/82\">",
"      Wu C, Lee AY. Malignancy and venous thrombosis in the critical care patient. Crit Care Med 2010; 38:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/83\">",
"      Robinson S, Zincuk A, Str&oslash;m T, et al. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010; 14:R41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/84\">",
"      Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011; 140:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/85\">",
"      Meyer CS, Blebea J, Davis K Jr, et al. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg 1995; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/86\">",
"      Schellong SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost 2007; 5:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/87\">",
"      Hull RD, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/88\">",
"      Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/89\">",
"      Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/90\">",
"      Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/91\">",
"      Alikhan R, Cohen AT. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 2003; 89:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/92\">",
"      Jois-Bilowich P, Michota F, Bartholomew JR, et al. Venous thromboembolism prophylaxis in hospitalized heart failure patients. J Card Fail 2008; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/93\">",
"      Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/94\">",
"      Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/95\">",
"      Sj&auml;lander A, Jansson JH, Bergqvist D, et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med 2008; 263:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/96\">",
"      Lentine KL, Flavin KE, Gould MK. Variability in the use of thromboprophylaxis and outcomes in critically ill medical patients. Am J Med 2005; 118:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/97\">",
"      Kanaan AO, Silva MA, Donovan JL, et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007; 29:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/98\">",
"      Dunn AS, Brenner A, Halm EA. The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical inpatients. Thromb Haemost 2006; 95:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/99\">",
"      Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007; 369:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/100\">",
"      Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996; 76:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/101\">",
"      Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/102\">",
"      Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost 2012; 108:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/103\">",
"      Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/104\">",
"      Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/105\">",
"      Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/106\">",
"      Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/107\">",
"      Hull RD, Schellong SM, Tapson VF, et al. Late breaking clinical trial: Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent mobility: the EXCLAIM study (abstract). J Thromb Haemost 2007; 5(Suppl 1):O-S-001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/108\">",
"      Bump GM, Dandu M, Kaufman SR, et al. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. J Hosp Med 2009; 4:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/109\">",
"      McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 2006; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/110\">",
"      Laporte S, Liotier J, Bertoletti L, et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost 2011; 9:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/111\">",
"      Hillbom M, Eril&auml; T, Sotaniemi K, et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002; 106:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/112\">",
"      Diener HC, Ringelstein EB, von Kummer R, et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 2006; 37:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/113\">",
"      Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest 2008; 133:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/114\">",
"      Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med 2011; 184:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/115\">",
"      PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/116\">",
"      Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/117\">",
"      Cohen AT, Spiro TE, B&uuml;ller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/118\">",
"      Albertsen IE, Larsen TB, Rasmussen LH, et al. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs 2012; 72:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/119\">",
"      Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost 2012; 10:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/120\">",
"      Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2009; :CD003747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/121\">",
"      King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 2007; 131:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/122\">",
"      Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 2011; 140:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/123\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/124\">",
"      Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/125\">",
"      Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/126\">",
"      Ageno W, Riva N, Noris P, et al. Safety and efficacy of low dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment. The FONDAIR study. J Thromb Haemost 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/127\">",
"      Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/128\">",
"      Karthikeyan G, Eikelboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009; 146:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/129\">",
"      Roberts VC, Sabri S, Beeley AH, Cotton LT. The effect of intermittently applied external pressure on the haemodynamics of the lower limb in man. Br J Surg 1972; 59:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/130\">",
"      Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/131\">",
"      Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008; :CD005258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/132\">",
"      Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; :CD001484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/133\">",
"      Andr&eacute; C, de Freitas GR, Fukujima MM. Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles. Eur J Neurol 2007; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/134\">",
"      CLOTS Trials Collaboration, Dennis M, Sandercock PA, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/135\">",
"      S&oslash;rensen HT, Horvath-Puho E, S&oslash;gaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/136\">",
"      Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/137\">",
"      Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009; 7:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/138\">",
"      Rabinowich L, Steinvil A, Leshem-Rubinow E, et al. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation. Heart 2012; 98:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/139\">",
"      Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/140\">",
"      Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/141\">",
"      Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/142\">",
"      Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/143\">",
"      Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011; 124:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/144\">",
"      Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9:e1001310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/145\">",
"      Cushman M. A new indication for statins to prevent venous thromboembolism? Not yet. J Thromb Haemost 2009; 7:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/146\">",
"      Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007; 147:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/147\">",
"      Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/148\">",
"      Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     www.asra.com (Accessed on October 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/21/36186/abstract/150\">",
"      Fiumara K, Piovella C, Hurwitz S, et al. Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thromb Haemost 2010; 103:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1346 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36186=[""].join("\n");
var outline_f35_21_36186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROBLEM OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Decision support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS FOR VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extended travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8747283\">",
"      - Admission to intensive care units",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overall approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5138262\">",
"      VTE risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23758764\">",
"      Bleeding risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5137505\">",
"      Values and preferences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5139523\">",
"      Making the decision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PHARMACOLOGIC AGENTS FOR VTE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5137695\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5137702\">",
"      Extended duration prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Heparins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Low dose unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Unfractionated versus LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MECHANICAL METHODS OF THROMBOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Graduated compression stockings and venous foot pump",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      VTE PREVENTION IN HEALTHY SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Group versus individual recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Patients at high risk of bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Neuraxial anesthesia or analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Medical center policies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Assignment of risk group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Specific recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3024506\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/54/875\" title=\"table 1\">",
"      Ideal prophylactic method VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/6/1132\" title=\"table 2\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_21_36187="Centruroides scorpion envenomation grades";
var content_f35_21_36187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Scorpion sting evaluation and treatment in the United States and Mexico",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"5%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"47%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Localized pain or paresthesias at site",
"       </td>",
"       <td>",
"        Symptomatic care, ie, analgesics, anxiolytics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Local and remote pain or paresthesias",
"       </td>",
"       <td>",
"        Symptomatic care, ie, analgesics, anxiolytics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        III",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Localized pain with paresthesias and either:",
"       </td>",
"       <td rowspan=\"4\">",
"        Symptomatic care and supportive care, ie, analgesics, anxiolytics; give antivenom if available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cranial nerve abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Somatic skeletal neuromuscular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Localized pain, cranial nerve abnormalities, somatic skeletal neuromuscular dysfunction, and airway involvement are all present",
"       </td>",
"       <td>",
"        Symptomatic care and supportive care, ie, analgesics, anxiolytics; give antivenom if available",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Grading scale and treatment following envenomation with Centruroides species.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36187=[""].join("\n");
var outline_f35_21_36187=null;
var title_f35_21_36188="Etiology of headache children";
var content_f35_21_36188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of headache in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Localized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated with URI (sinusitis, otitis media) or viral infection (influenza)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Related to oral cavity (dental abscess, TMJ dysfunction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brain abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        First migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic infection (influenza)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central nervous system infection (meningitis, viral encephalitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertension, hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exertional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        First migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxins (eg, carbon monoxide), medications (eg, amphetamines, oral contraceptives), or illicit substances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute and recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cluster headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic and non-progressive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tension-type headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric (depression, school phobia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic, postconcussive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication overuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic and progressive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic intracranial hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Space-occupying lesion (tumor, abscess, hemorrhage, hydrocephalus, vascular malformation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic, postconcussive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     URI: upper respiratory infection; TMJ: temporomandibular joint.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Morton L. Headache. In: Clinical Handbook of Pediatrics, Schwartz MW (Ed), Williams and Wilkins, Baltimore 1995, p.316.",
"       </li>",
"       <li>",
"        Rothner DA. Headache in adolescence. Adolescent Health Update. 2006; 18:1.",
"       </li>",
"       <li>",
"        Strasburger VC, Brown RT, Braverman PK, et al. Headache. In: Adolescent Medicine A Handbook for Primary Care, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.25.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36188=[""].join("\n");
var outline_f35_21_36188=null;
var title_f35_21_36189="Asthma and FRs NFRs";
var content_f35_21_36189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Indicators of severe persistent or uncontrolled asthma in patients experiencing fatal and near-fatal reactions after AIT injections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36189=[""].join("\n");
var outline_f35_21_36189=null;
var title_f35_21_36190="Incidence of CKD after nonrenal organ TPL";
var content_f35_21_36190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Graph showing incidence of chronic kidney disease following nonrenal solid organ transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of chronic renal failure (CRF), defined as an estimated glomerular filtration rate &le;29 mL/min per 1.73 m2, among 69,321 persons who received nonrenal solid organ transplants in the United States between January 1, 1990, and December 31, 2000. Cyclosporine was given to 60 percent and tacrolimus to 28 percent. Measurements of renal function were obtained at six-month intervals during the first year and annually thereafter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ojo, AO, Held, PJ, Port, FK, et al, N Engl J Med 2003; 349:931.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36190=[""].join("\n");
var outline_f35_21_36190=null;
var title_f35_21_36191="Smith Magenis syndrome";
var content_f35_21_36191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Smith-Magenis syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smith-Magenis syndrome (SMS)&nbsp;is typified by a microdeletion of chromosome band 17p11.2. Fluorescence in situ hybridization (FISH) analysis of a patient's chromsomes is shown. The green control probe shows that an unrelated region of chromosome 17 is present in both chromosomes 17. The red probe, which detects the 17p11.2 region commonly deleted in SMS, only fluoresces on a single chromosome. This finding strongly supports the diagnosis of SMS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Athena Cherry, Stanford Hospital and Clinics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_21_36191=[""].join("\n");
var outline_f35_21_36191=null;
